Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker    Newsletter   Tax Corner NRI Centre Forums E-Mail Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Tata Stl 506.35 1.52
Bhel 228.35 3.47
Tata Mot 524.65 3.51
Hindalco 163.35 1.74
Ong Corp 414.65 1.58
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Venus Remedies Limited
Venus Remedies Limited
Sector:Pharmaceuticals Pharmaceuticals - Pharmaceuticals - Others
BSE:526953NSE:VENUSREMBloomberg:VNR@INReuters:VENR.BO
Market Lot: 1Face Value: 10ISIN Demat: INE411B01019
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
16-SEP-14 Venus Remedies said that in reference to the downgrading of external rating by CRISIL, the company had availed a major part of the term loans for its ongoing 08-SEP-14 Venus Remedies, a research based pharmaceutical company, has entered into a distribution-cum-outlicensing agreement with Mylan for marketing its generic broad-spectrum antibiotic, meropenem, in three European countries. 04-SEP-14 Venus Remedies, a research based phar...   More..
Business Profile Future Plans
One To One
Recent news
Latest News
Venus Remedies climbs on pact with Mylan  -IRIS 08-Sep-14
Previous

More


Brief Financials (in Rs. Mn.) 
Period ending (months)31-Mar-2014 (12)31-Mar-2013 (12)31-Mar-2012 (12)
Net sales 5186.904590.974051.87
Other Income4.063.950.00
Total Income5190.964594.924051.87
Cost of goods sold3928.273428.503146.03
OPBDIT1262.691166.42905.84
PAT609.50571.45500.29
Gross Block---
Equity capital114.42105.4297.42
EPS (Rs.)54.1954.210.00
DPS (Rs.)---
BV (Rs.)---
P/E range (x)2.58 - 6.612.91 - 6.05NA
Debt / Equity (x)---
Operating margin (% of OI)24.325.422.4
Net margin (% of OI)11.712.412.3
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
SCO 857
Cabin No 10
IInd Floor
NAC Manimajra
Chandigarh
Union Territory-160 101
PHONE
- - -
FAX
- - -
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | E-mail | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer